First seen by DFX
Sep 16, 2026
date not stated
Palvella Therapeutics Appoints Accomplished Rare Disease Biotech Executive and Commercial Leader Matt Pauls, J.D., M.B.A., to Board of Directors June 2026 Read more on
First seen by DFX
Sep 16, 2026
date not stated
Petrichor Names Diagnostics Industry Leader Don Hardison as Operating Partner May 2026 Read more on
First seen by DFX
Sep 16, 2026
date not stated
Petrichor Names Paul Sekhri as Operating Partner April 2026 Read more on
First seen by DFX
Sep 16, 2026
date not stated
Egetis Completes the U.S. Rolling NDA Submission for Emcitate® (tiratricol) for Treatment of MCT8 Deficiency January 2026 Read more on
First seen by DFX
Sep 16, 2026
date not stated
Tourmaline Bio Enters into Agreement to be Acquired by Novartis AG September 2025 Read more on
First seen by DFX
Sep 16, 2026
date not stated
Alcon Acquires Majority Interest in Aurion Biotech, Inc. to Advance Innovative Cell Therapy for Corneal Endothelial Disease March 2025 Read more on
First seen by DFX
Sep 16, 2026
date not stated
Geneoscopy Closes $105M in Series C Funding Round to Power Next-Generation of Gastrointestinal Diagnostic Tests January 2025 Read more on
First seen by DFX
Sep 16, 2026
date not stated
Palvella Therapeutics Announces Closing of Merger with Pieris Pharmaceuticals and Concurrent Private Placement of $78.9 Million December 2024 Read more on
First seen by DFX
Sep 16, 2026
date not stated
Ascend Advanced Therapies Partners with EW Healthcare Partners to Expand United States Capacity and Capabilities November 2024 Read more on
First seen by DFX
Sep 16, 2026
date not stated
Palvella Therapeutics and Pieris Pharmaceuticals Announce Definitive Merger Agreement July 2024 Read more on
First seen by DFX
Sep 16, 2026
date not stated
Evergreen Theragnostics Completes $26M Capital Raise to Advance Novel Radiopharmaceutical Pipeline into the Clinic, Prepare for First Commercial Product Launch, and Expand Industry-Leading CDMO Services April 2024 Read more on
First seen by DFX
Sep 16, 2026
date not stated
Ascend acquires GMP manufacturing capacity in Alachua, Florida; Enters long-term partnership with Beacon Therapeutics for clinical and commercial AAV production April 2024 Read more on
First seen by DFX
Sep 16, 2026
date not stated
Avalo Acquires Anti-IL-1β mAb and Announces Private Placement Financing of up to $185 Million March 2024 Read more on
First seen by DFX
Sep 16, 2026
date not stated
Fennec announces incremental $5 million investment from Petrichor December 2023 Read more on
First seen by DFX
Sep 16, 2026
date not stated
Tourmaline Bio Announces Closing of Merger with Talaris Therapeutics and Concurrent Private Placement of $75 Million October 2023 Read more on
First seen by DFX
Sep 16, 2026
date not stated
ITM Announces €255m Investment Round, Plans to Advance Radiopharmaceutical Pipeline and to Expand Radioisotope Production Capacities June 2023 Read more on
First seen by DFX
Sep 16, 2026
date not stated
Fennec Pharmaceuticals Announces Second Closing of $20 Million Investment from Petrichor September 2022 Read more on Fennec Pharmaceuticals
First seen by DFX
Sep 16, 2026
date not stated
Fennec Pharmaceuticals Announces Up to $45 Million Investment From Petrichor August 2022 Read more on Fennec Pharmaceuticals
First seen by DFX
Sep 16, 2026
date not stated
Petrichor Managing Partner Tadd Wessel Joins the ICPO Foundation Board of Curators May 2022 Read more on ICPO
First seen by DFX
Sep 16, 2026
date not stated
LumiraDx to Become Publicly Traded following Successful Closing of Merger with CA Healthcare Acquisition Corp. September 2021 Read more on LumiraDx
First seen by DFX
Sep 16, 2026
date not stated
Petrichor Closes Oversubscribed Fund I at $410 Million November 2020
First seen by DFX
Sep 16, 2026
date not stated
Blackstone invests $275 million in Cryoport to fund acquisition of MVE Biological Solutions October 2020 Read more on Cision
First seen by DFX
Sep 16, 2026
date not stated
MRI Interventions, Inc. Obtains a $17.5 Million Strategic Investment from PTC Therapeutics, Inc. and Petrichor Healthcare Capital Management January 2020 Read more on ClearPoint Neuro
First seen by DFX
Sep 16, 2026
date not stated
Cryoport Announces $25 Million Investment from Petrichor Healthcare Capital Management December 2018 Read more on Cision
POF I Coinvest LP first reported on Form ADV by Petrichor Healthcare Capital Management LP (Private Equity Fund), GAV $61,426,887
Petrichor Opportunities Fund I Intermediate LP first reported on Form ADV by Petrichor Healthcare Capital Management LP (Private Equity Fund), GAV $159,855,291
Petrichor Opportunities Fund I LP first reported on Form ADV by Petrichor Healthcare Capital Management LP (Private Equity Fund), GAV $100,000,000